Teva announces positive results from a study assessing a new formulation of Copaxone.
<shortened url>
new formula
The text seems to contradict the conclusion of the study - 12.5% vs 18.1% for those with the new formulation suggests a relative risk INCREASE of nearly 50% for tolerability problems with the new formulation.
A typo? Anybody have a link to the original paper?
A typo? Anybody have a link to the original paper?
Adverse events were reported by 12.5 percent of patients when injecting 20mg/1.0mL and by 18.1 percent of patients when injecting 20mg/0.5mL.